



"The information provided in this newsletter is for educational and informational purposes only. Any new process, procedure, medication, or clinical trial should be discussed with your primary care physician before being considered or implemented."

Monthly Respiratory Newsletter

January 02, 2026

This newsletter summary captures the significant shifts in the Idiopathic Pulmonary Fibrosis (IPF) landscape as of late 2025. For the first time in over a decade, the medical community is moving beyond the "duopoly" of nintedanib and pirfenidone, with major global regulatory approvals and successful Phase 3 trials leading the way.

The Headline: Nerandomilast (JASCAYD®) Approved

After successful Phase 3 trials, Nerandomilast has received regulatory approval in the **USA and China**, with the **EU and Japan** expected to follow shortly. This is the first PDE4B inhibitor for IPF, designed to address both inflammation and the scarring of lung tissue.

What's New in the Pipeline?

- **Inhaled Treprostinil:** New data shows this inhaled treatment significantly supports lung function, offering an alternative to traditional oral medications.
- **Bexotegrast:** A dual integrin inhibitor that is moving into accelerated late-stage trials after showing potential to not just slow, but possibly improve, lung function in some cases.
- **AI-Enhanced Care:** Clinics worldwide are beginning to use AI to analyze lung scans, allowing doctors to customize treatment plans much faster than previously possible.

Global Clinical Trial Outlook

The shift is moving toward **combination therapy**. Much like treatments for other chronic conditions, the future of IPF care likely involves "cocktails" of different medications tailored to your specific genetic and physiological profile.

Contact Information / Resources:

- Oscar Escobar - eMail : naplesprclub@gmail.com